Literature DB >> 24133782

Lifetime risks of cutaneous melanoma by histological subtype and race/ethnicity in the United States.

Zhuang Feng1, Zhenzhen Zhang, Xiao-Cheng Wu.   

Abstract

The probability of developing melanoma of the skin in the United States has been previously reported as a whole entity. This study aimed to describe lifetime risks of cutaneous melanoma by histological subtype among different racial and ethnic groups in the United States. Melanoma cases newly diagnosed in 2005-2007 were obtained from 16 registries participating in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Lifetime risks of developing melanoma subtypes (nodular melanoma, lentigo maligna melanoma, superficial spreading melanoma, acral lentiginous melanoma and desmoplastic melanoma) were examined among non-Hispanic whites, Hispanic whites, Blacks, and Asian/Pacific Islanders. Of the total 43,690 melanoma cases, 18,910 cases (43%) diagnosed with one of the five histological subtypes were included in the study. The results reveal that lifetime risks of melanoma subtypes differ among racial and ethnic groups, and therefore, stratification of the risks by subtype provides useful information in evaluating and counseling patients.

Entities:  

Mesh:

Year:  2013        PMID: 24133782

Source DB:  PubMed          Journal:  J La State Med Soc        ISSN: 0024-6921


  3 in total

1.  Skin Cancer in People of Color: A Systematic Review.

Authors:  George A Zakhem; Akshay N Pulavarty; Jenna C Lester; Mary L Stevenson
Journal:  Am J Clin Dermatol       Date:  2021-12-13       Impact factor: 7.403

2.  Characteristics, rates, and trends of melanoma incidence among Hispanics in the USA.

Authors:  Erin Garnett; Julie Townsend; Brooke Steele; Meg Watson
Journal:  Cancer Causes Control       Date:  2016-03-28       Impact factor: 2.506

Review 3.  Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.

Authors:  Praveen K Bommareddy; Anand Patel; Saamia Hossain; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2017-02       Impact factor: 7.403

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.